title: Risk factors and clinical course of portal and/or splenic vein thrombosis after partial splenic embolization.
abstract: BACKGROUND
  Although portal and/or splenic vein thrombosis after partial splenic embolization (PSE) is a well-known complication, few reports evaluating risk factors have been published.
  
  
  OBJECTIVE
  To investigate risk factors and clinical course of portal and/or splenic vein thrombosis after PSE.
  
  
  METHODS
  Sixteen patients with severe hypersplenism underwent PSE between March 2005 and April 2008. The correlation between portal and/or splenic vein thrombosis after PSE detected on multidetector row CT (MDCT) and various factors were retrospectively reviewed. Further, the clinical course of portal and/or splenic vein thrombosis after PSE was observed on follow-up MDCT.
  
  
  RESULTS
  Splenic vein thrombosis was detected in eight patients (50%) on MDCT images taken within 9 days after PSE. In one, the thrombosis also involved the portal vein. The infarct volume was identified as a significant risk factor for portal and/or splenic vein thrombosis (P=0.046). In all but one patient, splenic vein thrombosis resolved completely or improved without anticoagulation therapy. In this patient, both portal and splenic vein thrombosis developed after PSE, and anticoagulation therapy was necessary.
  
  
  CONCLUSIONS
  It is suggested that a large splenic infarct volume is a risk factor for portal and/or splenic vein thrombosis after PSE. Indications for treatment of thrombosis of the portal vein system after PSE may be limited to patients with portal vein thrombosis.
authors.affiliation: Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kawaramachi Hirokoji, Kamigyo-ku, Kyoto, Japan. t-matsu@koto.kpu-m.ac.jp
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Takuji
authors.initials: T
authors.lastname: Yamagami
authors.forename: Koshi
authors.initials: K
authors.lastname: Terayama
authors.forename: Takeharu
authors.initials: T
authors.lastname: Kato
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Hirota
authors.forename: Rika
authors.initials: R
authors.lastname: Yoshimatsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miura
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Ito
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okanoue
authors.forename: Tsunehiko
authors.initials: T
authors.lastname: Nishimura
mesh_terms: D000328:Adult; D000368:Aged; D003287:Contrast Media; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D006971:Hypersplenism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D011169:Portal Vein / Q000000981:diagnostic imaging*; D011856:Radiographic Image Enhancement / Q000379:methods; D012189:Retrospective Studies; D012307:Risk Factors; D013162:Splenic Vein / Q000000981:diagnostic imaging*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000209:etiology
chemical_list: D003287:Contrast Media